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Tolerogenic dendritic cell (tolDC)-based therapies have become a promising approach for the treatment 
of autoimmune diseases by their potential ability to restore immune tolerance in an antigen-specific 
manner. However, the broad variety of protocols used to generate tolDC in vitro and their functional 
and phenotypical heterogeneity are evidencing the need to find robust biomarkers as a key point 
towards their translation into the clinic, as well as better understanding the mechanisms involved in 
the induction of immune tolerance. With that aim, in this study we have compared the transcriptomic 
profile of tolDC induced with either vitamin D3 (vitD3-tolDC), dexamethasone (dexa-tolDC) or 
rapamycin (rapa-tolDC) through a microarray analysis in 5 healthy donors. The results evidenced that 
common differentially expressed genes could not be found for the three different tolDC protocols. 
However, individually, CYP24A1, MUCL1 and MAP7 for vitD3-tolDC; CD163, CCL18, C1QB and C1QC for 
dexa-tolDC; and CNGA1 and CYP7B1 for rapa-tolDC, constituted good candidate biomarkers for each 
respective cellular product. In addition, a further gene set enrichment analysis of the data revealed that 
dexa-tolDC and vitD3-tolDC share several immune regulatory and anti-inflammatory pathways, while 
rapa-tolDC seem to be playing a totally different role towards tolerance induction through a strong 
immunosuppression of their cellular processes.
In the last decade, tolerogenic dendritic cells (tolDC) have become one of the most promising approaches for the 
treatment of immune-mediated disorders such as autoimmune diseases (i.e. type 1 diabetes, multiple sclerosis 
or rheumatoid arthritis), but also for allergies or transplant rejection. In a healthy organism, immature dendritic 
cells (iDC) are specialized antigen-capturing cells that, when exposed to a pro-inflammatory millieu, differenti-
ate into mature dendritic cells (mDC) in order to orchestrate an immunogenic response against the potentially 
pathogen-related peptide they previously recognized, captured and presented. Autoimmune disorders are char-
acterized by the loss of immune tolerance against determined self-peptides, thus causing a pathological response 
of the immune system that leads to different diseases depending on which antigen/s are equivocally attacked. In 
this context, the main advantage of potential tolDC-based therapies resides in their presumed role to restore the 
immune tolerance against self-peptides in an antigen-specific manner, acting only over the cause of the patho-
logic process without compromising the protective immunity from the patient.
A wide variety of protocols has been developed to generate tolDC in vitro, for instance by the action of sev-
eral immunomodulatory agents (such as 1,25-dihydroxycholecalciferol, the active form of vitamin D31–4, dexa-
methasone3–6 or rapamycin3,4,7), cytokines (IL-104,8, IFN-β4,9) or by genetic engineering10,11 and, in all cases, they 
remain stable against maturation. Furthermore, the leap from the bench to the bedside has already been taken, 
there existing several clinical trials, either completed or ongoing, that have demonstrated the safety of autologous 
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tolDC-based therapies in rheumatoid arthritis, type 1 diabetes and Crohn’s disease, while further studies to eval-
uate their actual efficacy are currently being developed11–16. However, the characteristics of these tolerogenic cells 
are heterogeneous depending on which protocol was used to differentiate them, presenting, for instance, variable 
phenotypical characteristics or producing different cytokines. For this reason, a wide range of analyses has to 
be carried out to characterize them. Currently, the most reliable evidence of the regulatory properties of tolDC 
comes given by functional assays. However, these tests normally take days and require the generation of control 
immunogenic conditions in parallel, which also translates into an increase in the cost of an already expensive 
production process due to the strict good manufacturing practice (GMP) conditions that are required to gener-
ate clinical grade tolDC. Therefore, the need for common pathways or strong biomarkers that could define the 
concept of tolerogenicity and unequivocally characterize tolDC is one of the pending questions to be answered, 
as they would help to better understand the molecular mechanisms of tolerance as well as saving time and money 
during the manufacturing of the cell products.
Vitamin D3, dexamethasone and rapamycin are three of the most widely used drugs to induce the differen-
tiation of tolDC in vitro. Our previous studies have shown that vitamin D3-induced tolDC (vitD3-tolDC) and 
dexamethasone-induced tolDC (dexa-tolDC) generate cells with rather similar characteristics in terms of pre-
senting a semi-mature phenotype, increased IL-10 secretion and reduced allogeneic T cell proliferation priming. 
In contrast, rapamycin-induced tolDC (rapa-tolDC) seemed to develop their tolerogenic role through regula-
tory T cell (Treg) induction, despite their mature phenotype and not secreting IL-10. In all cases, however, an 
allogeneic T cell proliferation suppression was observed, and the three tolDC types remained stable upon LPS 
re-stimulation3.
Consequently, provided the heterogenous characteristics of these cells, we performed a microarray analysis 
of vitD3-, dexa- and rapa-tolDC, differentiated from 5 healthy donors, in order to obtain their transcriptomic 
profile and look for common pathways and/or mechanisms of tolerance induction. Indeed, our hypothesis is that 
the identification and definition of these effector routes could provide useful biomarkers for the characterization 
of these cells, specially thinking of their application in future clinical trials, since they may be helpful to compare 
results in studies worldwide and thus accelerate the translation of tolDC-based therapies from the bench to the 
bedside.
Results
Gene expression analysis revealed two different transcriptomic profiles in tolDC. The preproc-
essing steps described in the methods section left 7864 probesets to be included in the analysis. In order to look 
for potential common biomarkers for the three tolDC conditions, the expression between each tolDC vs mDC, as 
well as between mDC vs iDC, was compared in cells differentiated from 5 healthy donors, using the linear models 
approach described in the methods section. Among them, an additional comparison was carried out between 
dexa-tolDC, rapa-tolDC and vitD3-tolDC versus both mDC and iDC, yielding a total of 1216 genes showing a 
statistically significant differential expression in at least one comparison (p-value < 0.01).
The representation of the transcriptomic profile of the 5 types of DC (iDC, mDC, dexa-tolDC, rapa-tolDC and 
vitD3-tolDC) in a heat map evidenced a segregation into two clusters of 492 and 724 genes with opposed expres-
sion (Fig. 1a). As expected, iDC and mDC exhibited an opposed genetic signature. However, rapa-tolDC showed 
a similar profile to mDC, while vitD3- and dexa-tolDC presented more resemblance to iDC.
TolDC showed several differentially expressed genes involved in the immune response modula-
tion, signaling and trafficking compared to mDC. To find the genes involved in the tolerogenic func-
tion of vitD3-, dexa- and rapa-tolDC, the expression of each tolDC condition was compared with the expression 
of mDC. The results are presented as mean differences of the signals (MeanDiff) for each gene, and the B-statistic 
values were also considered. As a result, only those genes presenting B > 0 and p < 0.01 values were selected for 
each of the different tolDC conditions, as they would constitute the most relevant and likely candidates for being 
involved in tolerance.
Figure 1. Comparative transcriptomic analysis of vitD3-tolDC, dexa-tolDC, rapa-tolDC, iDC and mDC. (a) 
Heat map representation of the transcriptomic expression profile of the different DC. Volcano plots of the top 
differentially expressed genes based on mean differences of expression (MeanDiff) and B scores of (b) dexa-
tolDC, (c) vitD3-tolDC and (d) rapa-tolDC versus mDC.
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When looking at the differentially expressed genes (DEG) between dexa-tolDC and mDC (Table 1), we found 
that there were several overexpressed genes (MeanDiff > 1.2) directly involved in immune-related functions 
such as the complement activation (C1QB and C1QC) and the immune-related chemotaxis (CCL18 and CCL26), 
while others are mainly involved in metabolism and cell interaction. In contrast, only 3 down-regulated genes 
(MeanDiff < −0.6) presented a positive value for the B-statistic, LSM14B (which may play a role in mRNA trans-
lation), FAM129A (a regulator of p53-mediated apoptosis) and PIWIL4 (involved in the development and main-
tenance of germline stem cells). The volcano-plot representation of the results can be observed in Fig. 1b.
In the case of vitD3-tolDC, the up- and down-regulated genes compared to mDC were not so directly 
related to immune functions (Table 1). Metabolism, as well as cell differentiation, structure and signaling, were 
the most predominant related functions, with genes such as MAP7, MUCL1 or SPARC strongly up-regulated 
(MeanDiff > 0.7). Nevertheless, genes encoding antimicrobial proteins (GZMB and CAMP) and proteins related 
with the direct metabolism of vitamin D3 (CYP24A1) could also be found, making a total of 9 up-regulated genes 
with B > 0. Among the down-regulated genes, only 3 fulfilled our criteria in the microarray, once again PIWIL4 
(demonstrating certain similarity between vitD3-tolDC and dexa-tolDC), TNFSF13B and DAPP1 (both out-
standing for being involved in immune regulation). All three of them showed strong reductions on their expres-
sion (MeanDiff < −0.6). The volcano-plot representation of the data is shown in Fig. 1c.
As for rapa-tolDC, as shown in Table 1, a total of 27 genes were selected. We found 3 genes with a strong 
up-regulation (MeanDiff > 2.2), encoding proteins developing innate immunity-related functions (CD1B, CD1C 
and CD1E), as well as, surprisingly, 2 genes related with the metabolism of fat soluble vitamins such as vitamin 
D3 (CNGA1 and CYP7B1). Among the down-regulated genes, most of them were related with the metabolism 
of different molecules and proteins, especially outstanding CTSB, ALDOC and GM2A for their high B values 
(>3) and their strong down-modulation (MeanDiff < −1.2). The down-modulation of FAS gene, mediating the 
induction of cell death, was also relevant. Analogously, a volcano-plot representation of the results in rapa-tolDC 
is shown in Fig. 1d.
A common genetic biomarker could not be found for the three tolDC conditions. Provided that 
a biomarker should unequivocally characterize a determined biological condition, we restricted even more our 
filtering parameters, selecting only those genes that were differentially expressed in the tolDC conditions versus 
both iDC and mDC at the same time. Once again, we made use of the P and B-statistic values as filtering criteria, 
selecting only those genes presenting B > 0 and p < 0.01 values for both comparisons. Consequently, we obtained 
those DEG that not only appeared to be differentially expressed, either over- or down-regulated, but that also 
their differential expression had high enough odds of being reliable.
As a result, 26 different genes, many of them already mentioned in the previous section, were compliant with 
the filtering parameters in at least one tolDC condition; 3 of them were overexpressed in vitD3-tolDC, 7 genes 
in dexa-tolDC and, in the case of rapa-tolDC, 4 genes were up-regulated and 13 were down-regulated (Fig. 2). 
Among all those genes, only CCL18 appeared in 2 out of the 3 tolDC conditions, showing a MeanDiff > 2.30 
in dexa-tolDC but a MeanDiff < −1.69 in rapa-tolDC (p-value < 0.01). As for the other reported genes, many 
of them were related with immune functions or cell differentiation, interaction or signaling mechanisms, such 
as MUCL1, MAP7, CD163, C1QB or C1QC, indicating important changes in the status of the different tolDC 
conditions respect of iDC and mDC that might be relevant for the tolerogenic function of the cells, or sim-
ply induced by the different tolerogenic agents used. These genes presented at least a MeanDiff > 0.79 for the 
up-regulated ones and a MeanDiff < −0.60 for those down-regulated. In all cases, statistical significance was 
reached (p < 0.01). These and further details can be found in Table 2.
VitD3 and dexa-tolDC share several common regulatory pathways, although none of them 
with rapa-tolDC. After determining which DEG could be found on each condition, we decided to perform 
a more comprehensive study of the transcriptome by analyzing which pathways and protein sets were up- or 
down-modulated on each DC condition. To do this, a Gene Set Enrichment Analysis (GSEA) was performed, and 
only those pathways and protein sets that showed a statistically significant enrichment (p-value < 0.05) on each 
tolDC condition compared to mDC were considered. Additionally, all those pathways that were up-modulated 
on iDC versus mDC were excluded as they would not constitute differential pathways of tolerance for our tolDC 
products, with the exception of the induction of Treg lymphocytes, immune response and hemophilic cell adhe-
sion via plasma membrane adhesion molecules protein sets, due to their functional relevance in tolerance. Finally, 
a total of 49 pathways and protein sets, differentially expressed versus mDC, were selected, either due to their 
relevance or for being shared between at least 2 tolDC conditions (Table 3). A graphical representation of them is 
presented in Fig. 3. The analysis could not reveal any pathway up- or down-modulated in common between the 
three tolDC conditions versus mDC.
When taking the comparisons two by two, a total of 18 pathways were simultaneously up-regulated in both 
dexa and vitD3-tolDC versus mDC, and 3 protein sets, mainly related with the plasma membrane, appeared 
up-regulated in dexa and rapa-tolDC versus mDC, with different behaviors regarding the comparisons between 
the remaining conditions. Any common enriched protein sets could be found between vitD3- and rapa-tolDC. 
Further 13 pathways were enriched at the same time in rapa-tolDC and either dexa or vitD3-tolDC, but with 
opposite modulation. Among these 34 mentioned protein sets, only 8 were differentially induced versus mDC in 
at least two tolDC conditions, being them dexa- and vitD3-tolDC in all cases, and with no differences between 
iDC and mDC. In addition, in 5 of those cases, the protein sets were also simultaneously down-modulated in 
rapa-tolDC. Of them, 3 were related with extracellular components (extracellular region, extracellular space and 
extracellular exosome) and the other 2 with a response to inflammation stimuli (inflammatory response and 
cellular response to IL-1).
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Gene EntrezID MeanDiff vs mDC B-statistic p-value GO annotations
dexa-tolDC
CD163 9332 3.70 6.08 <0.0001 Protein binding, scavenger receptor acivity
C1QC 714 2.83 3.39 <0.0001 Innate immune response, immune complement
C1QB 713 2.74 6.33 <0.0001 Innate immune response, immune complement
CCL26 10344 2.71 5.05 <0.0001 Chemotaxis, signal transduction, inflammatory response
CCL18 6362 2.34 4.79 <0.0001 Chemotaxis, signal transduction, inflammatory response
RNASE1 6035 2.16 2.59 <0.0001 Nucleic acid binding
SLC16A10 117247 1.83 1.45 0.0001 Amino acid transport
NPL 80896 1.57 3.37 <0.0001 Protein binding
RGL1 842953 1.40 0.11 0.0003 Protein binding
FMN1 342184 1.27 4.36 <0.0001 Microtubule cytoskeleton
LSM14B 149986 −0.91 0.15 0.0003 RNA binding
FAM129A 116496 −0.92 0.55 0.0002 Protein binding
PIWIL4 143689 −1.12 0.07 0.0004 RNA binding
vitD3-tolDC
ATP6V0D2 245972 2.42 1.64 0.0001 Protein binding
CYP24A1 1591 2.27 0.72 0.0002 Metabolism
MUCL1 118430 2.13 1.13 0.0001 Metabolism
ST6GAL1 6480 1.56 1.38 0.0001 Metabolism
CAMP 820 1.35 0.71 0.0002 Innate immune response
SPARC 6678 1.35 0.93 0.0001 Protein binding
SLC7A8 23428 1.27 0.62 0.0002 Amino acid transport
MAP7 9053 0.88 2.23 <0.0001 Microtubule cytoskeleton
GZMB 3002 0.74 0.34 0.0003 Protein binding, immunological synapse
PIWIL4 143689 −1.12 0.09 0.0004 RNA binding
TNFSF13B 10673 −1.15 1.25 0.0001 Protein binding
DAPP1 27071 −1.37 0.99 0.0001 Protein binding
rapa-tolDC
CD1B 910 3.56 5.12 <0.0001 Adaptive immune response
CD1E 913 3.09 3.38 <0.0001 Adaptive immune response
CNGA1 1259 2.40 3.46 <0.0001 Protein binding, plasma membrane
CD1C 911 2.29 0.09 0.0004 Adaptive immune response
CYP7B1 9420 1.95 1.63 0.0001 Oxidation-reduction process
LOC100128175 100128175 1.77 1.76 0.0001 N/A
KIAA1586 57691 1.13 1.34 0.0001 Ligase activity
SFMBT1 51460 0.88 0.08 0.0004 Protein binding, negative regulation of transctiption
FAM129A 116496 0.88 0.31 0.0003 Protein binding
PSIP1 11168 0.81 0.99 0.0001 RNA binding
PSAP 5660 −0.63 0.49 0.0003 Lipid binding
P4HB 5034 −0.66 0.48 0.0003 Metabolism
FTL 2512 −0.68 0.80 0.0002 Protein binding
FAS 355 −0.72 0.01 0.0005 Cell death induction
RRAGD 58528 −0.93 0.07 0.0004 Protein binding
SOAT1 6646 −0.99 0.05 0.0004 Protein binding
SERINC2 347735 −1.10 0.05 0.0004 Metabolism
SCD 6319 −1.12 1.40 0.0001 Oxidation-reduction process
TPP1 1200 −1.13 1.13 0.0001 Protein binding
CTSA 5476 −1.14 6.20 <0.0001 Protein metabolism
CTSB 1508 −1.26 3.32 <0.0001 Protein metabolism
ALDOC 230 −1.32 3.07 <0.0001 Protein binding
CTSD 1509 −1.35 1.14 0.0001 Protein metabolism
GM2A 2760 −1.37 4.19 <0.0001 Metabolism
GPNMB 10457 −2.18 0.30 0.0003 Protein binding
CCL18 6362 −2.47 6.23 <0.0001 Chemotaxis, signal transduction, inflammatory response
RSAD2 91543 −2.62 3.27 <0.0001 Protein binding
Table 1. Differentially expressed genes in dexa-tolDC, vitD3-tolDC and rapa-tolDC versus mDC. Results 
shown as mean difference of expression (MeanDiff). In all cases, B > 0 and p < 0.01. GO: Gene Ontology.
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Additionally, a GSEA was also performed comparing tolDC and mDC versus iDC, and in this case both 
nucleosome assembly and autoreactivity and multifocal inflammation protein sets were found differentially over-
expressed only in dexa, rapa and vitD3-tolDC at the same time, as there were no differences in their expression 
between iDC and mDC. However, again, the comparison of any pathway or biomarker in tolDC versus iDC could 
potentially provide results caused by the maturation process that these cells were exposed to, just like mDC, and 
not exclusively by the tolerogenic features of the cells. In fact, these same two protein sets did not show the same 
pattern in the previous GSEA versus mDC. Consequently, those sets which were upregulated in mDC versus iDC 
were excluded from the analysis. The results can be seen in Supplementary Table S1.
VitD3-tolDC presented an increased metabolic activity combined with a reduction in the apoptotic 
processes. When considering the pathways simultaneously regulated in vitD3-tolDC versus both iDC and 
mDC, we encountered that, as expected, those related with oxidative phosphorylation and the metabolism of 
vitamin D3 were overexpressed. In addition, the protein O-linked glycosylation pathway was also found over-
expressed in vitD3-tolDC in comparison to mDC, as already reported in previous studies17,18. Furthermore, the 
ERK1/2 signaling cascade and the SP1 signaling factor, both involved in important tolerogenic functions, were 
induced in vitD3-tolDC respect of mDC. Consequently, the tolerance-inducing functionality of vitD3-tolDC is 
suggested to be driven by the up-regulation of the Treg lymphocyte induction genes and an increased expression 
of the extracellular region protein set compared to both iDC and mDC, together with the results shown in the 
previous section. These protein sets contain, in fact, important immune-related genes such as CCL4 and CCL7, 
which determine T cell and monocyte chemotaxis respectively, as well as MUCL1, previously mentioned as a 
potential biomarker. Other up-regulated protein sets included viral and inflammatory response activities. In con-
trast, only the apoptosis pathway appeared to be differentially down-regulated in vitD3-tolDC. All the results are 
presented in Table 3 and Table 4.
A strongly down-regulated transcriptome is observed in rapa-tolDC. Contrary to vitD3-tolDC, 
the transcriptomic profile of rapa-tolDC was mostly consisting on down-modulated protein sets, evidencing 64 
pathways that were repressed in comparison with both iDC and mDC. Of note, many of these down-modulated 
pathways were related with inflammation, chemotaxis and lipid metabolism (Table 4). Among them, 11 of these 
protein sets were those that appeared simultaneously up-regulated in dexa- and vitD3-tolDC, as mentioned 
above. As for the rest, many signaling, metabolic and transportation processes were inhibited in rapa-tolDC, such 
as the ERK1 and ERK2 cascade or the glycosphingolipid metabolism and cholesterol transport. Moreover, several 
protein sets related with the inflammatory and innate immune responses were also found inhibited, evidencing 
the potent immunosuppressant effect of rapamycin. Confirming previous reports, and as therefore expected, the 
mTOR pathway also appeared down-modulated in rapa-tolDC referred to mDC but not to iDC19–21 (Table 3). On 
the other hand, only 3 protein sets were upregulated, being especially relevant the methylated histone binding 
and the DNA-templated transcription, as they indicate that deep changes might be happening regarding the DNA 
processing and epigenetics of rapa-tolDC.
Immune complement and macrophage features are expressed in dexa-tolDC. Similarly to 
vitD3-tolDC, dexa-tolDC presented a mostly up-regulated differential transcriptomic profile (Table 4). However, 
the induction of immune-related protein sets was much more relevant in this condition, with the positive regula-
tion of immune complement activation and macrophage chemotaxis pathways. In addition, the up-modulation 
of immunosuppressant and DC tolerogenicity protein sets, along with the induction of the ERK1/2 signaling 
Figure 2. Differentially expressed genes in vitD3-, dexa- or rapa-tolDC versus both iDC and mDC with a 
B-statistic value > 0. Results shown as mean difference of expression (MeanDiff).
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cascade and the SP1 transcription factor, supports the tolerogenic functionality of dexa-tolDC. Moreover, the 
increased expression of the extracellular region protein set was also directed towards the immune function, 
with CCL2, CCL4, CD163 and several other immune-related protein-encoding genes up-regulated. However, 
STAT1 appeared to be up-modulated in dexa-tolDC, which constituted an unexpected result due to its generally 
pro-inflammatory-related functionality. Another similarity with previously reported results for vitD3-tolDC was 
the up-modulation of the response to hypoxia also in dexa-tolDC17.
Discussion
The number of clinical trials using autologous tolDC to treat autoimmune diseases is increasing each year, 
and the first results from several phase I studies have demonstrated that this tolerogenic therapy is safe for the 
patients11–16. Therefore, the role of these cells is gaining a huge relevance in the field of personalized medicine. 
Due to the wide variety of protocols that exist nowadays to generate tolDC in vitro, a deep study of the cells gen-
erated by them has become of key importance to elucidate which mechanisms of tolerance induction are being 
triggered. Establishing adequate quality controls and biomarkers that can ensure not only the functionality but 
also the safety of tolDC has become one of the main concerns towards its translation into the clinic22. Thus, deter-
mining if common pathways of tolerance are being promoted or whether each treatment is activating different 
mechanisms in the cellular product is important, as it would set up the first steps towards the finding of potential 
biomarkers of tolDC. Ideally, however, they should be able to generically identify these cells despite the protocol 
used to generate them.
To our knowledge, our microarray analysis constitutes the first study directly comparing three of the most 
widely used tolDC-inducing protocols. Unfortunately, it was not possible to find a common DEG in the tran-
scriptomic profile of vitD3-, dexa- and rapa-tolDC. In fact, just a brief analysis of the whole transcriptomic profile 
looking at the heat map already evidenced that different protocols came with different prints, as rapa-tolDC 
showed not only a different but a completely opposite genetic signature compared to dexa- and vitD3-tolDC. 
These results are in accordance with a previous study by our group that evidenced different phenotypical and 
functional characteristics of dexa, rapa and vitD3-tolDC3. Our current study allowed us to go deeper in that 
direction and, in fact, we could identify some potential biomarkers for both rapa- and dexa-tolDC, CCL18 and 
FAM129A genes. However, they showed an opposed behavior pattern –while CCL18 appeared to be differentially 
induced in dexa-tolDC, it was down-modulated in rapa-tolDC, and vice versa for FAM129A–, evidencing that the 
Cell type Gene EntrezID Coding protein
MeanDiff B-statistic p-value
vs iDC vs mDC vs iDC vs mDC vs iDC vs mDC
vitD3-tolDC
CYP24A1 1591 Vitamin D3 24-Hydroxylase 2.86 2.27 3.54 0.72 <0.0001 0.0002
MUCL1 118430 Mucin-Like Protein 1 2.05 2.13 0.97 1.13 0.0002 0.0001
MAP7 9053 Microtubule Associated Protein 7 0.80 0.88 1.60 2.23 0.0001 <0.0001
dexa-tolDC
CD163 9332 Cluster of Differentiation 163 3.40 3.70 6.06 6.08 <0.0001 <0.0001
C1QC 714 Complement C1q C Chain 1.98 2.83 0.01 3.39 0.0005 <0.0001
C1QB 713 Complement C1q B Chain 1.50 2.74 0.04 6.33 0.0004 <0.0001
CCL18 6362 C-C Motif Chemokine Ligand 18 3.06 2.34 9.83 4.79 <0.0001 <0.0001
SLC16A10 117247 Solute Carrier Family 16 Member 10 1.92 1.83 2.37 1.45 <0.0001 0.0001
RGL1 842953 RalGDS-Like 1 1.61 1.40 1.76 0.11 0.0001 0.0003
FMN1 342184 Formin 1 1.01 1.27 2.21 4.36 <0.0001 <0.0001
rapa-tolDC
CNGA1 1259 Cyclic Nucleotide Gated Channel Alpha 1 2.42 2.40 3.77 3.46 <0.0001 <0.0001
CYP7B1 9420 Oxysterol 7-Alpha-Hydroxylase 3.00 1.95 7.67 1.63 <0.0001 0.0001
FAM129A 116496 Cell Growth-Inhibiting Gene 39 Protein 1.34 0.88 5.46 0.31 <0.0001 0.0003
PSIP1 11168 PC4 And SFRS1 Interacting Protein 1 1.31 0.81 7.49 0.99 <0.0001 0.0001
PSAP 5660 Prosaposin −0.72 −0.63 1.88 0.49 0.0001 0.0003
P4HB 5034 Prolyl 4-Hydroxylase Subunit Beta −0.98 −0.66 5.45 0.48 <0.0001 0.0003
FTL 2512 Ferritin Light Chain −0.97 −0.68 5.35 0.80 <0.0001 0.0002
RRAGD 58528 Ras Related GTP Binding D −1.10 −0.93 1.79 0.07 0.0001 0.0004
SOAT1 6646 Sterol O-Acyltransferase 1 −1.07 −0.99 0.72 0.05 0.0002 0.0004
TPP1 1200 Tripeptidyl Peptidase 1 −1.82 −1.13 7.71 1.13 <0.0001 0.0001
CTSA 5476 Cathepsin A −1.72 −1.14 13.71 6.20 <0.0001 <0.0001
CTSB 1508 Cathepsin B −2.03 −1.26 11.08 3.32 <0.0001 <0.0001
CTSD 1509 Cathepsin D −2.73 −1.35 11.59 1.14 <0.0001 0.0001
GM2A 2760 GM2 Ganglioside Activator −2.39 −1.37 13.72 4.19 <0.0001 <0.0001
GPNMB 10457 Glycoprotein NMB −3.73 −2.18 7.27 0.30 <0.0001 0.0003
CCL18 6362 C-C Motif Chemokine Ligand 18 −1.75 −2.47 1.94 6.23 0.0001 <0.0001
RSAD2 91543 Viperin −2.82 −2.62 4.48 3.27 <0.0001 <0.0001
Table 2. Differentially expressed genes in vitD3-tolDC, dexa-tolDC and rapa-tolDC versus both mDC and 
iDC. Results shown as mean difference of expression (MeanDiff). In all cases, B > 0 and p < 0.01.
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molecular tolerance-inducing mechanisms triggered by these two immunomodulatory agents must be different. 
Specifically, CCL18 is of a notorious relevance, since the cytokine encoded by this gene has been reported to have 
a fundamental role in the cell differentiation process towards the development of semi-mature DC with the ability 
to produce IL-10 and prime Treg23.
The fact that common candidate biomarkers could not be found for our three tolDC-inducing protocols, 
however, does not decrease the value of those genes that appeared as differentially expressed on each one of the 
studied conditions versus both iDC and mDC. For instance, as indicators of the up-regulation of the protein 
O-linked glycosylation, of the response to vitamin D treatment, and of the establishment of cell polarity, detected 
by the GSEA in vitD3-tolDC, MUCL1, CYP24A1, and MAP7 genes, respectively, were found strongly induced 
versus iDC and mDC at the same time. Provided that the O-linked glycosylation has been directly related with 
the regulation of microtubule-associated proteins of the cytoskeleton24, combined with previous studies report-
ing CYP24A1 and CAMP genes as directly related to the vitamin D3 metabolism25–28, all these genes apparently 
make good candidates to become strong biomarkers of vitD3-tolDC. Additionally, these candidates have also 
been related to many other key cell processes such as the glucose metabolism, stress response and cell cycle, as 
reviewed by Hart et al.29. Moreover, their discovery is also supported by the positive B-statistic values showed by 
these genes in the microarray. Further supporting our results, an induction of the oxidative metabolism could also 
be detected, which constitutes a key feature of vitD3-tolDC, as previously reported17.
In the case of dexa-tolDC, apart from CCL18, already discussed above, the overexpression of the genes encod-
ing CD163 and two different chains of the complement C1q protein (C1QB and C1QC) versus both iDC and 
mDC are the most relevant results as potential biomarkers, due to their immune-related implications. It is also 
worth mentioning that MERTK has been previously reported as a biomarker for dexa-tolDC in several studies6,30. 
Our results, however, do not evidence the differential expression of this gene, but it might be explained due to the 
intrinsic limitations of microarrays regarding false negatives results. As for CD163, its role in tolerance induction 
has already been reported in M2 macrophages but, so far, not for tolDC. We have also detected an enrichment 
on the macrophage chemotaxis protein set. Therefore, our results suggest that both regulatory macrophages and 
dexa-tolDC might be triggering similar tolerogenic mechanisms, probably through the STAT3 and Wnt5a signa-
ling pathway, as its interaction with CD163 has already been reported in cancer studies31,32. Regarding C1QB and 
C1QC genes, their overexpression is aligned with the up-modulation of the complement activation protein set. 
The role of the immune complement system, as a promoter of immune tolerance in dendritic cells, has been over-
looked until the last few years. Nevertheless, as reviewed by Luque et al.33, recent studies demonstrate that C1q is 
involved in key tolerogenic processes such as an increased surface PD-L2 and decreased CD86 expression, linked 
to a reduced induction of Th1 and Th17 proliferation34, the inhibition of the production of pro-inflammatory 
mediators35 and an increased production of anti-inflammatory cytokines, such as IL-1036,37. As a matter of fact, 
C1QB has previously been proposed as a potential biomarker for tolerogenicity38, and its differential expression 
along with other genes encoding the C1q protein has been reported in previous studies30. Therefore, our results 
seem to indicate that dexa-tolDC might be developing their tolerogenic properties through the mentioned mech-
anisms, among others that will be discussed below. Conversely, our microarray also detected an induction of 
the STAT1 signaling pathway, which has been reported as pro-inflammatory and opposed to STAT3, switching 
Figure 3. Graphical representation of the enriched pathways and protein sets in vitD3-, dexa- and/or rapa-
tolDC. The color code indicates the degree of enrichment of each protein set based on their ES, from red 
(ES = −1) to green (ES = 1) as indicated by the color scale bar.
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between both responses under the control of NOD1 after an IL-10-dependant activation39. However, other studies 
also reported that, in regulatory dendritic cells such as dexa-tolDC, STAT1 can be activated in response to TLR 
stimuli in order to attract Th1 cells through an increased CXCL10 production and subsequently inhibit them40.
Comparative studies between vitD3- and dexa-tolDC have been reported before, demonstrating many simi-
larities between the two conditions regarding their semi-mature status and the inhibition of allogeneic prolifera-
tion3, the NF-κB pathway suppression41–43 and the polarization of the immune response towards a Th2 profile44. 
Some differences, however, have been described regarding the antigen-specific induction of Treg45, and a pro-
teomic comparative study also evidenced differences in the protein expression profile, despite confirming that 
vitD3- and dexa-tolDC were very similar on the phenotypical and functional aspects46. Furthermore, most of 
the mentioned studies also evidenced that the effect of both drugs was syngeneic, enhancing the tolDC-inducing 
effect of vitamin D3 and dexamethasone when used in combination, instead of each one independently. In 
fact, this approach has even been tested on a clinical trial, with successful results regarding the tolerability and 
safety of the cell product16,47,48. Our study confirmed this resemblance between vitD3- and dexa-tolDC, as well 
as their tolerogenic potential, since a strong up-modulation of the ERK1/2 and SP1 pathways was observed in 
Table 3. Enriched protein sets in dexa-tolDC, rapa-tolDC, vitD3-tolDC and/or iDC versus mDC. Green arrow: 
upregulation of said set; Yellow bar: unchanged regulation of said set; Red arrow: downregulation of said set. 
BED: Biological Effectors Database; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; 
TRRUST: Transcriptional Regulatory Relationships Unraveled by Sentence-based Text-mining.
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both conditions, among other protein sets. These specific pathways have been reported to be involved in key 
mechanisms of tolerance induction, such as, TGF-ß secretion49–51, dendritic cell survival52, TLR-dependent and 
independent IL-10 production51,53,54, and functional stability55. Surprisingly, however, we could not find any DEG 
in common for both dexa- and vitD3-tolDC respect of mDC, despite sharing the induction of such key pathways.
In addition, our results also showed that not only rapa-tolDC do not share the up-regulation of any of the 
discussed pathways in common with the other studied tolDC conditions, but that they are even down-modulated 
Table 4. Enriched pathways and protein sets, versus both iDC and mDC, in vitD3-tolDC, rapa-tolDC 
and dexa-tolDC. Green arrow: upregulation of said set; Yellow bar: unchanged regulation of said set; Red 
arrow: downregulation of said set. BED: Biological Effectors Database; GO: Gene Ontology; KEGG: Kyoto 
Encyclopedia of Genes and Genomes; TRRUST: Transcriptional Regulatory Relationships Unraveled by 
Sentence-based Text-mining.
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after rapamycin treatment. Furthermore, mTOR signaling has been reported as a crucial and even indispensable 
mechanism to maintain the tolerogenic functionality of vitD3- and dexa-tolDC in some of the same reports cited 
above17,55. Therefore, and provided that rapamycin is, indeed, the natural inhibitor of the mTOR signaling path-
way, the transcriptomic and functional incompatibility of both dexa- and vitD3-tolDC with rapa-tolDC becomes 
evident. Consequently, our results suggest that different mechanisms might be triggered in rapa-tolDC to induce 
immune tolerance.
The down-modulation of the mTOR signaling by the response to rapamycin constitutes the main signature 
of these cells, and through the inhibition of its dependent pathways, several immune-related mechanisms have 
been reported to play a role in the induction of tolerance, as reviewed by Stallone et al.56. For instance, rapa-
mycin has been described to both induce the up-regulation of CCR7 and dampen the production of IL-10 in 
monocyte-derived DC, but also that the surface expression of the former is inhibited by the latter57. Furthermore, 
the rapamycin-mediated inhibition of mTOR also reportedly induces the expression of ILT3 and ILT4 in DC, 
through the down-modulation of CD40, in order to prime Foxp3+ Treg and switch the immune response towards 
a Th2 profile58. Consequently, and in accordance to our results, the low IL-10 secretion by rapa-tolDC is function-
ally logical and demonstrates that tolerance can be achieved by different mechanisms that look apparently contra-
dictory at first sight. Apart from the inhibition of mTOR, the effect of rapamycin comes along with the repression 
of many other immune-related genes, pathways and proteins. Many of them are involved in pro-inflammatory 
and chemotactic processes, thus demonstrating the strong immunosuppressant effect of this drug. In fact, while 
only overexpressed genes could be detected as potential biomarkers in the case of vitD3- and dexa-tolDC, for 
rapa-tolDC, from a total of 17 selected DEG, 13 of them were repressed and only 4 appeared up-modulated 
respect both iDC and mDC. A similar situation was evidenced for the selected protein sets after the GSEA analy-
sis, both exclusively and in comparison to the other tolDC conditions, as discussed above.
In any case, the incapability to find common biomarkers arises the idea that, although a normalized tran-
scriptomic profile of immune tolerance induction might not be achieved, at least a small pool of the most repre-
sentative genes of each condition, constituting a “generic” tolDC signature, could be established. Nevertheless, 
it is worth stating that single results obtained from microarrays are highly prone to be biased, as the generally 
low B-statistic values found in our results suggest. Therefore, we cannot fully discard the possibility of having 
overlooked a determined universal genetic biomarker of tolerance, just like we did, for instance, with MERTK in 
dexa-tolDC. Nevertheless, this scenario seems unlikely given the strong differences that we have observed among 
the transcriptomic profiles of our tolDC conditions, and that were confirmed by the GSEA. Indeed, enrichment 
analyses provide an increased reliability to microarray studies, as they are based in the grouped expression of 
genes instead of single results and, as a matter of fact, many of the genes and pathways found in our array for 
each individual tolDC protocol have been previously reported and even evidenced in similar transcriptomic and 
proteomic studies7,17,30,46,59, thus strengthening our results.
In conclusion, and despite further validation is required, CYP24A1, MUCL1, MAP7, CD163, CCL18, C1QB, 
C1QC, CYP7B1 and CNGA1 genes, among several others, have been identified as potential biomarkers for the 
different individual tolDC-generating protocols. Furthermore, we have also been able to identify several path-
ways that are being differentially modulated by the pharmacological tolDC-inducing treatments, suggesting that 
immune tolerance is a complex status that can be achieved through different mechanisms. After all, several pub-
lications have demonstrated the capability of these protocols to generate functional immune regulatory cells, 
despite their differences. This functional heterogenicity, however, also suggest that determined tolDC-inducing 
protocols might be more suitable than others for the treatment of specific autoimmune diseases. For instance, 
a defect on the functionality and activation of Treg has been described in patients with type 1 diabetes and 
myasthenia gravis60–62. Consequently, based on both the literature and our current and previous results3,45,56,58, 
vitD3-tolDC and rapa-tolDC might constitute better therapeutic alternatives than dexa-tolDC in these two spe-
cific examples, since the induction of Treg plays an important role in their tolerogenic functionality. On the other 
hand, in diseases in which the presence of autoreactive T cells plays a main role, such as multiple sclerosis63,64, the 
vitD3-tolDC-mediated induction of hyporesponsiveness over these pathologic cells might have a more beneficial 
effect. However, this is far from demonstrated yet and, provided the complexity of the mechanisms of tolerance 
induction within the immune system, several in vitro experiments and clinical trials should be conducted in order 
to compare the efficacy of different protocols. In any case, and although our results seem to indicate that finding 
a common biomarker of tolerogenicity might be utopic, they also reinforce the role of tolDC as a promising ther-
apeutic approach for the immediate future.
Methods
Sample collection and in vitro tolDC generation. Five samples from healthy donors of iDC, mature 
mDC and the three conditions of tolDC differentiated in the presence of either vitamin D3 (vitD3-tolDC), dex-
amethasone (dexa-tolDC) or rapamycin (rapa-tolDC) were selected from previous experiments by our group3. 
The Ethical Committee of Germans Trias i Pujol Hospital approved the study, and all subjects gave their informed 
consent according to the Declaration of Helsinki (BMJ 1991; 302: 1994). Briefly, for the DC differentiations, buffy 
coats provided by the Banc de Sang i Teixits (Barcelona, Spain) were processed, first depleting T CD3+ cells 
using a RosetteSep Human CD3 Depletion Cocktail (StemCell Technologies, Vancouver, Canada) during a ficoll-
hypaque (Rafer, Zaragoza, Spain) gradient separation and later isolating monocytes by positive selection using the 
EasySep Human CD14 Positive Selection Kit (StemCell Technologies). In all cases, purity was greater than 95% 
and viability greater than 90%. Monocytes were cultured for 6 days in cGMP-grade X-VIVO 15 medium, sup-
plemented with 100 U/mL penicillin and 100 µg/mL streptomycin, in the presence of 1000 U/mL clinical-grade 
granulocyte-macrophage colony- stimulating factor (GM-CSF; CellGenix, Freiburg, Germany) and 1000 U/mL 
clinical-grade interleukin 4 (IL-4; CellGenix). Respectively, half and total volume of fresh medium and cytokines 
were replenished on days 2 and 4. All the conditions except for iDC were treated on day 4 with a maturation 
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cocktail of clinical-grade cytokines containing 1000 U/mL tumor necrosis factor alpha (TNFα; CellGenix), 10 ng/
mL IL-1β (CellGenix) and 1 µM prostaglandin E2 (PGE2; Pfizer, New York, NY, USA). While mDC did not 
receive any additional stimulus, the different tolDC conditions were obtained adding either 1 nM vitamin D3 
(Calcijex, Abbott, Chicago, IL, USA) on days 0 and 4, 1 µM dexamethasone (Fortecortín, Merck, Spain) on days 2 
and 4 or 10 nM rapamycin (Rapamune, Wyeth, Spain) on days 2 and 4. In order to determine optimal and compa-
rable concentrations of each of these immunomodulatory agents, dose-dependent experiments were set up using 
mDC as reference. Cells were harvested on day 6 for further characterization and functional assays, and later 
centrifuged and stored as dry pellets at −80 °C. The complete characterization of vitD3-, dexa- and rapa-tolDC 
regarding phenotype, cytokine secretion and functionality can be found in our previous study by Naranjo-Gómez 
et al.3.
Preparation of RNA samples and microarray analysis. Total RNA was isolated from the dry pellet 
samples using RNeasy Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions, and RNA 
Integrity Number (RIN) was assessed. Only samples with good quality were considered (RIN ≥ 6). Total RNA 
was later retrotranscribed, and the resulting cDNA was further preamplified using the Ovation® PicoSL WTA 
System V2 kit (NuGEN Technologies, San Carlos, CA, USA) at the Unitat Cientificotècnica de Suport of the Vall 
d’Hebron Research Institute (Barcelona, Spain), due to the low amount of RNA initially obtained in some of the 
samples (1–300 ng). Subsequently, the cDNA was fragmented, labeled and hybridized to the 33297 probes of a 
GeneChip 1.0 microarray chip (Affymetrix, Santa Clara, CA, USA). The statistical analysis was performed using 
R software and the libraries developed for microarray data analysis by the Bioconductor Project (www.biocon-
ductor.org). All the samples demonstrated high quality cDNA characteristics, with a 3′/5′ ratio of probe sets for 
glyceraldehyde-3-phosphate dehydrogenase and beta-actin of <1.5.
Differentially expressed genes selection. All the images generated by the microarray were processed at 
the Department of Statistics from the University of Barcelona. The raw data obtained from the image (“CEL”) files 
were pre-processed using the robust multi-array average method65, which performs a three-step process consist-
ing of background correction, normalization and summarization at gene level. The resulting expression values 
were then submitted to a two-step non-specific filtering process; First, those genes whose mean signal per group 
was below the 50th percentile of all signals were removed. From the remaining genes, those whose standard devi-
ation was below the 50th percentile of all standard deviations were further filtered out. These normalized filtered 
values were used for all the analysis. The selection of DEG was based on a linear model analysis with empirical 
Bayes moderation of the variance estimates, following the methodology developed by Smyth66. The Benjamini 
and Hochberg method67 was used to adjust the p-values in order to obtain a strong control over the false discov-
ery rate. For each gene, B-statistic values were calculated. Briefly, this parameter roughly indicates the logarithm 
of the odds of a gene to be effectively differentially expressed, and the higher the B value, the more likely that one 
determined result is reliable.
Identification of enriched pathways and protein sets. A GSEA was performed by Anaxomics 
(Barcelona, Spain) over our microarray data in order to determine the presence of enriched pathways and protein 
sets between our different tolDC conditions, following previously described methodology68. The analysis was 
performed over protein sets from several databases, including Gene Ontology (GO) terms (biological process, 
cellular component and molecular function) according to the European Molecular Biology Laboratory-European 
Bioinformatics Institute (EMBL-EBI)/UniProt-GO69, Biological Effectors Database (BED, property of 
Anaxomics), Kyoto Encyclopedia of Genes and Genomes (KEGG)70, Pharmacogenomics Knowledgebase 
(PharmGKB)71, Small Molecule Pathway Database (SMPDB)72 and the regulatory molecular mechanisms 
included in the Transcriptional Regulatory Relationships Unraveled by Sentence-based Text-mining (TRRUST) 
database73. The degree of enrichment of a determined protein set was evaluated based on their respective enrich-
ment score (ES). Cytoscape 3.5.1. software was used to create the representation of the common and individual 
enriched protein sets between each tolDC condition, based on their ES score.
Accession code. Microarray data have been deposited in the ArrayExpress database at EMBL-EBI 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-6937 (https://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-6937).
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